291 related articles for article (PubMed ID: 21512405)
1. Safety and efficacy of first-line bevacizumab with chemotherapy in Asian patients with advanced nonsquamous NSCLC: results from the phase IV MO19390 (SAiL) study.
Tsai CM; Au JS; Chang GC; Cheng AC; Zhou C; Wu YL
J Thorac Oncol; 2011 Jun; 6(6):1092-7. PubMed ID: 21512405
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of first-line bevacizumab combination therapy in Chinese population with advanced non-squamous NSCLC: data of subgroup analyses from MO19390 (SAiL) study.
Zhou CC; Bai CX; Guan ZZ; Jiang GL; Shi YK; Wang MZ; Wu YL; Zhang YP; Zhu YZ
Clin Transl Oncol; 2014 May; 16(5):463-8. PubMed ID: 24002945
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study.
Crinò L; Dansin E; Garrido P; Griesinger F; Laskin J; Pavlakis N; Stroiakovski D; Thatcher N; Tsai CM; Wu YL; Zhou C
Lancet Oncol; 2010 Aug; 11(8):733-40. PubMed ID: 20650686
[TBL] [Abstract][Full Text] [Related]
4. First-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer : analysis of the Italian patients enrolled in the SAiL study.
Bearz A; Passalacqua R; Alabiso O; Cinieri S; Gridelli C; Cravesana C; Crinò L
Clin Drug Investig; 2012 Nov; 32(11):755-60. PubMed ID: 23018280
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: safety of avastin in lung trial (MO19390).
Laskin J; Crinò L; Felip E; Franke F; Gorbunova V; Groen H; Jiang GL; Reck M; Schneider CP
J Thorac Oncol; 2012 Jan; 7(1):203-11. PubMed ID: 22173662
[TBL] [Abstract][Full Text] [Related]
6. MO19390 (SAiL): bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC.
Dansin E; Cinieri S; Garrido P; Griesinger F; Isla D; Koehler M; Kohlhaeufl M
Lung Cancer; 2012 Jun; 76(3):373-9. PubMed ID: 22236866
[TBL] [Abstract][Full Text] [Related]
7. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
Cohen MH; Gootenberg J; Keegan P; Pazdur R
Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.
Johnson DH; Fehrenbacher L; Novotny WF; Herbst RS; Nemunaitis JJ; Jablons DM; Langer CJ; DeVore RF; Gaudreault J; Damico LA; Holmgren E; Kabbinavar F
J Clin Oncol; 2004 Jun; 22(11):2184-91. PubMed ID: 15169807
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.
Reynolds C; Barrera D; Jotte R; Spira AI; Weissman C; Boehm KA; Pritchard S; Asmar L
J Thorac Oncol; 2009 Dec; 4(12):1537-43. PubMed ID: 19887966
[TBL] [Abstract][Full Text] [Related]
10. BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.
Zhou C; Wu YL; Chen G; Liu X; Zhu Y; Lu S; Feng J; He J; Han B; Wang J; Jiang G; Hu C; Zhang H; Cheng G; Song X; Lu Y; Pan H; Zheng W; Yin AY
J Clin Oncol; 2015 Jul; 33(19):2197-204. PubMed ID: 26014294
[TBL] [Abstract][Full Text] [Related]
11. BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer.
Hainsworth JD; Fang L; Huang JE; Karlin D; Russell K; Faoro L; Azzoli C
J Thorac Oncol; 2011 Jan; 6(1):109-14. PubMed ID: 21107290
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.
Patel JD; Hensing TA; Rademaker A; Hart EM; Blum MG; Milton DT; Bonomi PD
J Clin Oncol; 2009 Jul; 27(20):3284-9. PubMed ID: 19433684
[TBL] [Abstract][Full Text] [Related]
13. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
14. Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer.
William WN; Kies MS; Fossella FV; Liu DD; Gladish G; Tse WH; Lee JJ; Hong WK; Lippman SM; Kim ES
Cancer; 2010 May; 116(10):2401-8. PubMed ID: 20225327
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of efficacy and safety of bevacizumab combined with chemotherapy for Chinese patients with advanced non-small cell lung cancer].
Zhao X; Wang M; Zhang L; Li L; Zhong W
Zhongguo Fei Ai Za Zhi; 2012 Jan; 15(1):6-10. PubMed ID: 22237117
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536.
Kim ES; Moon J; Herbst RS; Redman MW; Dakhil SR; Velasco MR; Hirsch FR; Mack PC; Kelly K; Heymach JV; Gandara DR
J Thorac Oncol; 2013 Dec; 8(12):1519-28. PubMed ID: 24189513
[TBL] [Abstract][Full Text] [Related]
17. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
Socinski MA; Jotte RM; Cappuzzo F; Orlandi F; Stroyakovskiy D; Nogami N; Rodríguez-Abreu D; Moro-Sibilot D; Thomas CA; Barlesi F; Finley G; Kelsch C; Lee A; Coleman S; Deng Y; Shen Y; Kowanetz M; Lopez-Chavez A; Sandler A; Reck M;
N Engl J Med; 2018 Jun; 378(24):2288-2301. PubMed ID: 29863955
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer.
Niho S; Kunitoh H; Nokihara H; Horai T; Ichinose Y; Hida T; Yamamoto N; Kawahara M; Shinkai T; Nakagawa K; Matsui K; Negoro S; Yokoyama A; Kudoh S; Kiura K; Mori K; Okamoto H; Sakai H; Takeda K; Yokota S; Saijo N; Fukuoka M;
Lung Cancer; 2012 Jun; 76(3):362-7. PubMed ID: 22244743
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab plus platinum-based chemotherapy: in advanced non-small cell lung cancer.
Wagstaff AJ; Keam SJ; McCormack PL
BioDrugs; 2009; 23(3):187-96. PubMed ID: 19627170
[TBL] [Abstract][Full Text] [Related]
20. A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy-Naïve Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer.
Marrone KA; Zhou X; Forde PM; Purtell M; Brahmer JR; Hann CL; Kelly RJ; Coleman B; Gabrielson E; Rosner GL; Ettinger DS
Oncologist; 2018 Jul; 23(7):859-865. PubMed ID: 29487223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
